Specialty Pharmacy

Andexanet can reverse anticoagulated-related bleeding in patients with acute major bleeding.

Several mechanisms can lead to BRAF inhibitor resistance among patients with melanoma.

Top news of the day from across the health care landscape.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of the CSI Specialty Group, discusses difficulties for an independent specialty pharmacy in the current landscape.

Lymph node staging carries a clinical significance in lung cancer patients.

Direct-acting antivirals can cure hepatitis C in most patients, but the drugs don’t eliminate complications, such as cirrhosis and liver cancer.

Specialty pharmacy data and specialty accreditations often can lead to multiple revenue streams.

The heavy reliance on MRI abnormalities and the tendency of multiple sclerosis to resemble other rare diseases leads to misdiagnoses.

United Nations Program on HIV and AIDS seeks to reach 90% of HIV patients administered antiretroviral therapy to achieve durable viral suppression.

Rinku A. Patel, PharmD, RPh, founder and CEO of KloudScript, discusses technological advances on the horizon that may improve specialty pharmacy operations.

Top news of the day from across the health care landscape.

Research targets formation of esophageal cancer tumors.

Viekira XR consists of three oral tablets taken once a day.

Nebivolol shows promise blocking anthracycline-induced cardiotoxicity in breast cancer patients.

Pharmacokinetics of anticoagulant tecarfarin not compromised by renal function as seen with warfarin.

Success of live birth can be influenced by genetic factors during in vitro fertilization therapy.

The Centers for Medicare and Medicaid Services takes action to improve Affordable Care Act exchanges.

Research reveals potential drug targets for cervical cancer associated with human papillomavirus.

New data reveals only a portion of hepatitis C positive individuals receive treatment.

Bioethicist calls attention to urgent need for HIV treatment efforts in pregnant women worldwide.

Delivery method may improve treatment for patients with Neimann Pick Type C1 disease.

Response times found to be 10% slower in people with Crohn’s disease than those without the disease.

Top news of the week in oncology, and cancer drug development.

New research compares cardiovascular issues among patients with type 2 diabetes and psoriasis.

Transmission rates reduced 96% among couples who both received treatment.

Novel drug is a bispecific T cell engager (BiTE) that targets the B-cell maturation antigen in multiple myeloma.

Top news of the day from across the health care landscape.

Underlying mechanisms of skin cancer reveal potential avenue to cure melanoma.